Recombinant SeV-hFGF2/dF Injection for PAOD

NCT03668353 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

PAOD - Peripheral Arterial Occlusive Disease
PAD
Critical Limb Ischemia

Interventions

BIOLOGICAL: Recombinant SeV-hFGF2/dF Injection

Sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd.